Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Mol Cancer Ther
; 10(12): 2298-308, 2011 Dec.
Article
in En
| MEDLINE
| ID: mdl-21926191
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyridines
/
Cell Growth Processes
/
Anilides
/
Neoplasm Metastasis
/
Neoplasms
/
Neovascularization, Pathologic
Type of study:
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Mol Cancer Ther
Journal subject:
ANTINEOPLASICOS
Year:
2011
Type:
Article
Affiliation country:
United States